checkAd

     380  0 Kommentare Orion Corporation's publication schedules for financial reporting in 2016

    ORION CORPORATION      STOCK EXCHANGE RELEASE 28 JULY 2015 at 9.45 a.m. EEST          


    Orion Corporation's publication schedules for financial reporting in 2016


    Orion Corporation will publish its Financial Statement Release 2015 on Tuesday, 2 February 2016.


    The publication dates of the Interim Reports in 2016 are as follows:


    Interim Report January-March 2016                    Wednesday, 27 April 2016
    Interim Report January-June 2016                      Tuesday, 19 July 2016
    Interim Report January-September 2016             Tuesday, 25 October 2016

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Orion Corp B!
    Short
    39,08€
    Basispreis
    1,34
    Ask
    × 5,44
    Hebel
    Long
    29,50€
    Basispreis
    0,71
    Ask
    × 5,05
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    The Financial Statements and the report of the Board of Directors 2015 will be published on the Company's website at the latest in week 9/2016.


    The Annual General Meeting is planned to be held on Tuesday, 22 March 2016 in Helsinki.


    Orion's financial reports and related presentation material are available on the Group's website at http://www.orion.fi/investors promptly after the publishing. The website also provides a possibility to register on Orion's mailing lists for releases. 
      
    Orion Corporation

     
    Timo Lappalainen
    President and CEO
      Olli Huotari
    SVP, Corporate Functions
     

                                                                           

    Publisher:
    Orion Corporation
    Communications
    Orionintie 1A, FI-02101 Espoo, Finland
    Homepage: www.orion.fi

    Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler® pulmonary drugs.
    Orion's net sales in 2014 amounted to EUR 1,015 million and the Company had about 3,500 employees. Orion's A and B shares are listed on NASDAQ Helsinki.




    This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
    The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
    Source: Orion Oyj via Globenewswire

    HUG#1941634



    GlobeNewswire
    0 Follower
    Autor folgen

    Verfasst von GlobeNewswire
    Orion Corporation's publication schedules for financial reporting in 2016 ORION CORPORATION      STOCK EXCHANGE RELEASE 28 JULY 2015 at 9.45 a.m. EEST           Orion Corporation's publication schedules for financial reporting in 2016 Orion Corporation will publish its Financial Statement Release 2015 on …

    Schreibe Deinen Kommentar

    Disclaimer